Peripheral artery disease and amputations with Sodium-Glucose co-Transporter-2 (SGLT-2) inhibitors: A Meta-analysis Of Randomized Controlled Trials.

[1]  B. Zinman,et al.  Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. , 2019, The New England journal of medicine.

[2]  Declare–Timi Investigators.  Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes , 2019 .

[3]  Deepak L. Bhatt,et al.  Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes , 2019, The New England journal of medicine.

[4]  Marc P. Bonaca,et al.  SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials , 2019, The Lancet.

[5]  M. Ridderstråle,et al.  Empagliflozin compared with glimepiride in metformin‐treated patients with type 2 diabetes: 208‐week data from a masked randomized controlled trial , 2018, Diabetes, obesity & metabolism.

[6]  Hui Wang,et al.  Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial , 2018, Diabetes Care.

[7]  S. Engel,et al.  Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo‐controlled randomized study , 2017, Diabetes, obesity & metabolism.

[8]  K. Mahaffey,et al.  Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes , 2017, The New England journal of medicine.

[9]  U. Broedl,et al.  Empagliflozin as add‐on to metformin in people with Type 2 diabetes , 2015, Diabetic medicine : a journal of the British Diabetic Association.

[10]  B. Zinman,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.

[11]  C. Kovacs,et al.  Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus. , 2015, Clinical therapeutics.

[12]  J. Rosenstock,et al.  Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78‐week randomized, double‐blind, placebo‐controlled trial , 2015, Diabetes, obesity & metabolism.

[13]  E. Araki,et al.  Long‐term treatment with empagliflozin as add‐on to oral antidiabetes therapy in Japanese patients with type 2 diabetes mellitus , 2015, Diabetes, obesity & metabolism.

[14]  V. Woo,et al.  Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double‐blind placebo‐controlled 102‐week trial , 2015, Diabetic medicine : a journal of the British Diabetic Association.

[15]  Dacheng Liu,et al.  Combination of Empagliflozin and Linagliptin as Second-Line Therapy in Subjects With Type 2 Diabetes Inadequately Controlled on Metformin , 2015, Diabetes Care.

[16]  G. Bakris,et al.  Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease , 2014, Diabetes, obesity & metabolism.

[17]  Lawrence A. Leiter,et al.  Canagliflozin Provides Durable Glycemic Improvements and Body Weight Reduction Over 104 Weeks Versus Glimepiride in Patients With Type 2 Diabetes on Metformin: A Randomized, Double-Blind, Phase 3 Study , 2014, Diabetes Care.

[18]  Lawrence A Leiter,et al.  Dapagliflozin Added to Usual Care in Individuals with Type 2 Diabetes Mellitus with Preexisting Cardiovascular Disease: A 24‐Week, Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Study with a 28‐Week Extension , 2014, Journal of the American Geriatrics Society.

[19]  J. Rosenstock,et al.  Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes , 2014, Diabetes Care.

[20]  A. Mithal,et al.  Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. , 2014, The lancet. Diabetes & endocrinology.

[21]  V. Woo,et al.  Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years , 2014, Diabetes, obesity & metabolism.

[22]  J. Bolinder,et al.  Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin , 2014, Diabetes, obesity & metabolism.

[23]  D. Kohan,et al.  Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control , 2013, Kidney international.

[24]  E. Ferrannini,et al.  Long-Term Safety and Efficacy of Empagliflozin, Sitagliptin, and Metformin , 2013, Diabetes Care.

[25]  A. Januszewicz,et al.  Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial , 2013, Diabetologia.

[26]  J. Rosenstock,et al.  Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea , 2013, Diabetes Care.

[27]  B. Bode,et al.  Efficacy and Safety of Canagliflozin Treatment in Older Subjects With Type 2 Diabetes Mellitus: A Randomized Trial , 2013, Hospital practice.

[28]  T. Mansfield,et al.  Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial , 2013, BMC Medicine.

[29]  B. Epstein,et al.  Dapagliflozin: A Novel Sodium‐Glucose Cotransporter Type 2 Inhibitor for the Treatment of Type 2 Diabetes Mellitus , 2012, Pharmacotherapy.

[30]  S. Del Prato,et al.  Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin , 2011, Diabetes Care.

[31]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement , 2009, BMJ : British Medical Journal.